Brief: AB Science Authorised To Initiate Phase II Study In Patients With Severe Mast Cell Activation Syndrome

AB Science SA

19/01/2022 17:17

Jan 19 (Reuters) - AB SCIENCE SA  ABS.PA :
    * REG-AB SCIENCE HAS BEEN GRANTED AUTHORIZATION TO INITIATE
PHASE
II STUDY IN PATIENTS WITH SEVERE MAST CELL ACTIVATION SYNDROME
BY THE FRENCH HEALTH AUTHORITY (ANSM)
    * STUDY AB20006 HAS ALSO BEEN APPROVED BY U.S. FOOD AND DRUG
ADMINISTRATION (FDA)
    * STUDY WILL ENROLL 60 PATIENTS FROM NUMEROUS STUDY CENTERS
    * THERE ARE CURRENTLY NO APPROVED THERAPIES FOR SEVERE MCAS
OR
DRUGS IN CLINICAL DEVELOPMENT FOR THIS INDICATION

Source text for Eikon:  ID:nGNE7HwcQC 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))